162 completed, 28 recruiting, 28 unknown, 22 terminated. 106 Phase 2, 57 Phase 3, 49 Phase 1, 41 Phase 4, 7 Early Phase 1.
Follow Abatacept: new trials by email Literature Review of Abatacept trials Research Report on Abatacept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 90 | 2026-07-08 | 2026-10-13 |
| Treatment of Antibody-Mediated Rejection (ABMR) With CarBel Carfilzomib, Belatacept - Kidney Transplant Rejection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2026-05-27 | 2026-10-23 |
| Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> Belatacept, anticalcineurins - Kidney Diseases | Phase 4 | Recruiting | University Hospital, Rouen | 44 | 2026-04-30 | 2026-06-09 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Duke University | 400 | 2026-01-09 | 2026-10-21 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT Abatacept - Hematologic Malignancy | Early Phase 1 | Recruiting | Duke University | 10 | 2025-11-12 | 2026-01-16 |
| Study of COYA 302 for the Treatment of ALS COYA 302, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Active not recruiting | Coya Therapeutics | 120 | 2025-10-01 | 2026-10-13 |
| Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 64 | 2025-09-03 | 2026-01-26 |
| Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach Placebo, Abatacept 10 mg/kg - Cardiovascular Diseases, Inflammation | Early Phase 1 | Withdrawn | University of Utah | 2025-09-01 | 2026-01-12 | |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor Ruxolitinib, Abatacept (Orencia) - Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 60 | 2025-05-10 | 2025-11-20 |
| Belatacept in Heart Transplantation Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium - Heart Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 66 | 2025-01-29 | 2026-10-09 |
| Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects Abatacept - Rheumatoid Arthritis (RA | Phase 1 | Completed | Kashiv BioSciences, LLC | 300 | 2024-07-04 | 2026-06-12 |
| Advancing Transplantation Outcomes in Children Sirolimus, Belatacept, Mycophenolate Mofetil - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2024-05-22 | 2026-10-23 |
| A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept - Rheumatoid Arthritis | Completed | Pfizer | 21340 | 2024-05-15 | 2025-07-31 | |
| Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Ruxolitinib, Abatacept - Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Recruiting | Washington University School of Medicine | 41 | 2024-05-07 | 2026-04-22 |
| IL-2 Plus Abatacept in FTD Abatacept plus Aldesleukin - Frontotemporal Degeneration | Phase 1 | Unknown | The Methodist Hospital Research Institute | 10 | 2024-05-06 | 2025-03-10 |
| Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination Tacrolimus, Belatacept - HBV, Kidney Transplantation | Unknown | University Hospital, Grenoble | 66 | 2024-03-15 | 2024-03-13 |
Showing 20 of 269. Sign in to see all of them.
Arthritis, Rheumatoid (92) · Graft vs Host Disease (13) · Diabetes Mellitus, Type 1 (9) · Arthritis (8) · Arthritis, Psoriatic (8) · Arthritis, Juvenile (7) · Lupus Erythematosus, Systemic (7) · Anemia, Sickle Cell (6) · Myelodysplastic Syndromes (6) · Vasculitis (5) · COVID-19 (4) · Delayed Graft Function (4) · Dermatomyositis (4) · Giant Cell Arteritis (4) · Granulomatosis with Polyangiitis (4)
Bristol-Myers Squibb (81) · National Institute of Allergy and Infectious Diseases (NIAID) (17) · NYU Langone Health (6) · Brigham and Women's Hospital (5) · Duke University (5) · Emory University (5) · University of California, Los Angeles (5) · Assistance Publique - Hôpitaux de Paris (4) · Columbia University (4) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (4) · Massachusetts General Hospital (4) · University of Erlangen-Nürnberg Medical School (4) · Boston Children's Hospital (3) · Karolinska Institutet (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)
United States (182) · Canada (40) · France (40) · Germany (35) · Mexico (29) · United Kingdom (28) · Italy (24) · Argentina (22) · Belgium (22) · Spain (22) · Australia (21) · Netherlands (19) · Brazil (17) · Russia (16) · South Africa (16)
Julian Mackay-Wiggan, MD, MS (3) · Kenneth Newell, MD, PhD (3) · Madhav Thambisetty, MD, PhD (3) · Rishi J Desai, PhD (3) · Carol A Langford, MD, MHS (2) · Carol A. Langford, MD, MHS (2) · Christian P. Larsen, MD, DPhil (2) · Flavio Vincenti, MD (2) · Idelberto R Badell, MD (2) · Jacalyn Rosenblatt, MD (2) · Jeffrey P Krischer, PhD (2) · Leslie Kean, MD, PhD (2) · Nicole Turgeon, MD (2)
PMID 29329602, PMID 22504093, PMID 27229685, PMID 28376912, PMID 31819995, PMID 33452173, PMID 37221146, PMID 37453737, PMID 16785475, PMID 17425783, PMID 17921185, PMID 18055472, PMID 18383390, PMID 18402714, PMID 18632147, PMID 19273451, PMID 20191582, PMID 20533545, PMID 20597110, PMID 21051752, PMID 21128258, PMID 21618201, PMID 21719096, PMID 21821865, PMID 21917824, PMID 22806274, PMID 22915624, PMID 23097311, PMID 23169319, PMID 23292882, PMID 23438305, PMID 23529285, PMID 23606702, PMID 23962455, PMID 24047754, PMID 24323392, PMID 24504810, PMID 24574239, PMID 24584926, PMID 24684552, PMID 24754273, PMID 24786925, PMID 24834977, PMID 25005467, PMID 25367713, PMID 25403681, PMID 25539805, PMID 25550337, PMID 25676427, PMID 25698370
2016 (4), 2014 (2), 2015 (2), U54AR057319 (2), UC4DK117009 (2), UM1AI109565 (2), 1UM1AI110557 (1), 2009 (1), 2018 (1), 2019 (1), 268200700036C-5-0-1 (1), R01AG060395 (1), U01AI084150 (1), U01AI138909 (1), U01DK061055 (1)